NUGEN MEDICAL DEVICES INC (NGMD.CA) Fundamental Analysis & Valuation

TSX-V:NGMD • CA67054F1009

Current stock price

0.02 CAD
0 (0%)
Last:

This NGMD.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. NGMD.CA Profitability Analysis

1.1 Basic Checks

  • In the past year NGMD has reported negative net income.
  • In the past year NGMD has reported a negative cash flow from operations.
NGMD.CA Yearly Net Income VS EBIT VS OCF VS FCFNGMD.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 -2M -4M -6M -8M

1.2 Ratios

Industry RankSector Rank
ROA -16.43%
ROE N/A
ROIC N/A
ROA(3y)-85.48%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NGMD.CA Yearly ROA, ROE, ROICNGMD.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 200 -200 400 -400

1.3 Margins

  • NGMD's Gross Margin has declined in the last couple of years.
  • NGMD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 54.96%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.27%
GM growth 5YN/A
NGMD.CA Yearly Profit, Operating, Gross MarginsNGMD.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 0 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. NGMD.CA Health Analysis

2.1 Basic Checks

  • NGMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for NGMD has been increased compared to 1 year ago.
  • The debt/assets ratio for NGMD is higher compared to a year ago.
NGMD.CA Yearly Shares OutstandingNGMD.CA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 50M 100M 150M 200M
NGMD.CA Yearly Total Debt VS Total AssetsNGMD.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • NGMD has an Altman-Z score of -3.34. This is a bad value and indicates that NGMD is not financially healthy and even has some risk of bankruptcy.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -3.34
ROIC/WACCN/A
WACC5.03%
NGMD.CA Yearly LT Debt VS Equity VS FCFNGMD.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 5M -5M 10M 15M

2.3 Liquidity

  • A Current Ratio of 5.84 indicates that NGMD has no problem at all paying its short term obligations.
  • A Quick Ratio of 5.60 indicates that NGMD has no problem at all paying its short term obligations.
Industry RankSector Rank
Current Ratio 5.84
Quick Ratio 5.6
NGMD.CA Yearly Current Assets VS Current LiabilitesNGMD.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2M 4M 6M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. NGMD.CA Growth Analysis

3.1 Past

  • NGMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.63%, which is quite impressive.
  • The Revenue for NGMD has decreased by -22.72% in the past year. This is quite bad
  • Measured over the past years, NGMD shows a very strong growth in Revenue. The Revenue has been growing by 94.29% on average per year.
EPS 1Y (TTM)76.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.71%
Revenue 1Y (TTM)-22.72%
Revenue growth 3Y94.29%
Revenue growth 5YN/A
Sales Q2Q%-93.47%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NGMD.CA Yearly Revenue VS EstimatesNGMD.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 200K 400K 600K 800K 1M

More info and screens

Find the best growth stocksShow best growing peers

0

4. NGMD.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for NGMD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NGMD.CA Price Earnings VS Forward Price EarningsNGMD.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NGMD.CA Per share dataNGMD.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.01 -0.02 -0.03 -0.04

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. NGMD.CA Dividend Analysis

5.1 Amount

  • No dividends for NGMD!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NGMD.CA Fundamentals: All Metrics, Ratios and Statistics

NUGEN MEDICAL DEVICES INC

TSX-V:NGMD (3/19/2026, 7:00:00 PM)

0.02

0 (0%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)12-01
Earnings (Next)04-28
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners2.39%
Ins Owner ChangeN/A
Market Cap4.54M
Revenue(TTM)589.50K
Net Income(TTM)-2.12M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.7
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.02
FCFYN/A
OCF(TTM)-0.02
OCFYN/A
SpS0
BVpS-0.02
TBVpS-0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -16.43%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 54.96%
FCFM N/A
ROA(3y)-85.48%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-8.27%
GM growth 5YN/A
F-Score3
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.84
Quick Ratio 5.6
Altman-Z -3.34
F-Score3
WACC5.03%
ROIC/WACCN/A
Cap/Depr(3y)0.73%
Cap/Depr(5y)N/A
Cap/Sales(3y)0.86%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%39.71%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-22.72%
Revenue growth 3Y94.29%
Revenue growth 5YN/A
Sales Q2Q%-93.47%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y39.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.79%
OCF growth 3YN/A
OCF growth 5YN/A

NUGEN MEDICAL DEVICES INC / NGMD.CA Fundamental Analysis FAQ

What is the fundamental rating for NGMD stock?

ChartMill assigns a fundamental rating of 1 / 10 to NGMD.CA.


Can you provide the valuation status for NUGEN MEDICAL DEVICES INC?

ChartMill assigns a valuation rating of 0 / 10 to NUGEN MEDICAL DEVICES INC (NGMD.CA). This can be considered as Overvalued.


How profitable is NUGEN MEDICAL DEVICES INC (NGMD.CA) stock?

NUGEN MEDICAL DEVICES INC (NGMD.CA) has a profitability rating of 0 / 10.


How financially healthy is NUGEN MEDICAL DEVICES INC?

The financial health rating of NUGEN MEDICAL DEVICES INC (NGMD.CA) is 2 / 10.